Company news

Innoviva, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

May 10, 2023

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 8, 2023

Innoviva Announces Retirement of Board Chairman

April 27, 2023

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

April 16, 2023

Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

March 12, 2023

Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

February 27, 2023

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

November 29, 2022

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 8, 2022

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

October 18, 2022

La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022

October 13, 2022

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

October 11, 2022

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 7, 2022

Innoviva Completes Acquisition of La Jolla Pharmaceutical

August 21, 2022

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

July 26, 2022

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment

July 12, 2022

Innoviva to Acquire La Jolla Pharmaceutical Company

July 10, 2022

Innoviva Completes Acquisition of Entasis Therapeutics

July 10, 2022

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

July 7, 2022

Innoviva to Acquire Entasis Therapeutics

May 22, 2022

Innoviva Reports First Quarter 2022 Financial Results

April 26, 2022

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

March 30, 2022

Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes

March 2, 2022

Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes

March 1, 2022

Innoviva Reports Fourth Quarter 2021 Financial Results

February 8, 2022

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

February 8, 2022

Innoviva Reports Third Quarter 2021 Financial Results

October 26, 2021

Innoviva Reports Second Quarter 2021 Financial Results

July 27, 2021

Innoviva Announces Strategic Repurchase of GSK’s Equity Stake

May 19, 2021

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

May 2, 2021

Innoviva Reports First Quarter 2021 Financial Results

April 27, 2021

Innoviva Reports Fourth Quarter 2020 Financial Results

February 2, 2021

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs

January 26, 2021

Innoviva Reports Third Quarter 2020 Financial Results

October 27, 2020

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

September 8, 2020

Innoviva Reports Second Quarter 2020 Financial Results

July 28, 2020

Innoviva Names Pavel Raifeld as Chief Executive Officer

May 20, 2020

Innoviva Reports First Quarter 2020 Financial Results

April 28, 2020

Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020

March 30, 2020

Innoviva Reports Fourth Quarter 2019 Financial Results

February 4, 2020

Innoviva Reports Third Quarter 2019 Financial Results

October 29, 2019

← Newer news releases

Decks

The 5 newest of 17 decks. Every deck is listed under its year.